Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Morphiex Biotherapeutics
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Morphiex is developing MBT-001, a unique dual-function CD47 immune checkpoint inhibitor that blocks both “don’t eat me” (CD47) and Thrombospondin-1 signals; it reportedly activates multiple immune cells to kill cancer and avoids typical red blood cell toxicity, but has not yet published clinical results[1][6].
- Therapeutic areas
- OncologyHematology
- Modalities
- AntibodyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Morphiex Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Morphiex Biotherapeutics.